Summit Therapeutics Shares Down as 4Q Loss Widens

Dow Jones

Feb 24, 2025

By Adriano Marchese

Summit Therapeutics shares fell after the company reported a wider loss in the fourth quarter.

Shares were trading 14% lower at $19.11.

The biopharmaceutical oncology company reported a loss of $61.2 million, or 8 cents a share, compared with a loss of $36.6 million, or 5 cents a share a year earlier.

Expenses also rose. Adjusted operating expenses came to $54.8 million from $27.7 million.

Additionally, Summit Therapeutics plans to work with Pfizer to study its promising cancer drug candidate ivonescimab and Pfizer's antibody drug conjugates in solid tumors.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

February 24, 2025 10:19 ET (15:19 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2513477353"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2513477353\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2513477353?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-24 23:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2513477353","market":"sh","top_or_hot":-1,"title":"Summit Therapeutics Shares Down as 4Q Loss Widens","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre>\n \n</pre>\n<p>\n  Summit <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares fell after the company reported a wider loss in the fourth quarter. \n</p>\n<p>\n  Shares were trading 14% lower at $19.11. \n</p>\n<p>\n  The biopharmaceutical oncology company reported a loss of $61.2 million, or 8 cents a share, compared with a loss of $36.6 million, or 5 cents a share a year earlier. \n</p>\n<p>\n  Expenses also rose. Adjusted operating expenses came to $54.8 million from $27.7 million. \n</p>\n<p>\n  Additionally, Summit Therapeutics plans to work with Pfizer to study its  promising cancer drug candidate ivonescimab and Pfizer's antibody drug conjugates in solid tumors. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 24, 2025 10:19 ET (15:19 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Summit Therapeutics Shares Down as 4Q Loss Widens</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSummit Therapeutics Shares Down as 4Q Loss Widens\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-02-24 23:19</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre>\n \n</pre>\n<p>\n  Summit <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares fell after the company reported a wider loss in the fourth quarter. \n</p>\n<p>\n  Shares were trading 14% lower at $19.11. \n</p>\n<p>\n  The biopharmaceutical oncology company reported a loss of $61.2 million, or 8 cents a share, compared with a loss of $36.6 million, or 5 cents a share a year earlier. \n</p>\n<p>\n  Expenses also rose. Adjusted operating expenses came to $54.8 million from $27.7 million. \n</p>\n<p>\n  Additionally, Summit Therapeutics plans to work with Pfizer to study its  promising cancer drug candidate ivonescimab and Pfizer's antibody drug conjugates in solid tumors. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 24, 2025 10:19 ET (15:19 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0321505439.SGD","symbol_name":"Schroder ISF Global Dividend Maximiser A Acc SGD","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2513477353","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2513477353","pubTimestamp":1740410340,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Summit Therapeutics shares fell after the company reported a wider loss in the fourth quarter.The biopharmaceutical oncology company reported a loss of $61.2 million, or 8 cents a share, compared with a loss of $36.6 million, or 5 cents a share a year earlier.Expenses also rose. Adjusted operating expenses came to $54.8 million from $27.7 million.Additionally, Summit Therapeutics plans to work with Pfizer to study its  promising cancer drug candidate ivonescimab and Pfizer's antibody drug conjugates in solid tumors.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU0234572021.USD":"高盛美国核心股票组合Acc","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","BK4592":"伊斯兰概念","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","LU0058720904.USD":"联博国际健康护理基金A","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4588":"碎股","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","SMMT":"Summit Therapeutics PLC","SG9999001176.USD":"United Global Healthcare Acc USD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","BK4007":"制药","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","SMMF":"Summit Financial Group","BK4211":"区域性银行","SG9999002232.USD":"Allianz Global High Payout USD","LENZ":"Therapeutics","BK4581":"高盛持仓","BK4599":"减肥药","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC"},"translate_title":"随着第四季度亏损扩大，Summit Therapeutics股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SMMF":1,"SMMT":0.9,"LENZ":1},"content_text":"By Adriano Marchese \n\n\n \n\n\n  Summit Therapeutics shares fell after the company reported a wider loss in the fourth quarter. \n\n\n  Shares were trading 14% lower at $19.11. \n\n\n  The biopharmaceutical oncology company reported a loss of $61.2 million, or 8 cents a share, compared with a loss of $36.6 million, or 5 cents a share a year earlier. \n\n\n  Expenses also rose. Adjusted operating expenses came to $54.8 million from $27.7 million. \n\n\n  Additionally, Summit Therapeutics plans to work with Pfizer to study its  promising cancer drug candidate ivonescimab and Pfizer's antibody drug conjugates in solid tumors. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 24, 2025 10:19 ET (15:19 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}